iRegene key facts
as of Oct 2026- Developer of chemically-derived allogeneic cell therapies aims to provide first-in-class treatments for major degenerative diseases.
- iRegene is valued at approximately $568.6M as of Oct 2026 (last reported valuation).
- It has raised $392.8M; the latest was Later Stage VC ($41.9M) in Sep 2025.
- Notable investors include Northern Light Venture Capital, Vertex Ventures China, GSR United Capital, Orinno Capital, Lotus Lake Ventures — 14 tracked in total.
- Status: Privately Held (backing).
iRegene's last reported valuation, Apr 2025. Nothing priced has surfaced since.
- ·The complete investor list: 14 names
- ·Watch iRegene: the Monday email on marks, rounds and moves
iRegene funding rounds
No funding rounds for iRegene are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs iRegene
14+iRegene valuation
iRegene's last reported valuation was $569 million in Apr 2025. No priced round, secondary trade or fund mark has surfaced since.
iRegene investors
14 investors are on record for iRegene, including Northern Light Venture Capital, Vertex Ventures China, GSR United Capital and Orinno Capital.
About iRegene
Developer of chemically-derived allogeneic cell therapies aims to provide first-in-class treatments for major degenerative diseases. The company leverages proprietary platforms and a pipeline led by NouvNeu001 for Parkinson's Disease to serve patients with conditions such as retinal degeneration and ischemic stroke, enabling faster-acting, disease-reversing therapeutic options.
- Sector
- Healthcare
- HQ
- Wuhan, China
- Founded
- 2017
- Employees
- 62
- Website
- cn.iregene.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.